A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Geron Corp stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 162,440 shares of GERN stock, worth $648,135. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,440
Previous 189,225 14.16%
Holding current value
$648,135
Previous $802,000 8.1%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$4.17 - $4.99 $111,693 - $133,657
-26,785 Reduced 14.16%
162,440 $737,000
Q2 2024

Jul 26, 2024

SELL
$3.1 - $5.09 $12,245 - $20,105
-3,950 Reduced 2.04%
189,225 $802,000
Q1 2024

Apr 24, 2024

SELL
$1.75 - $3.44 $56,346 - $110,761
-32,198 Reduced 14.29%
193,175 $637,000
Q4 2023

Feb 09, 2024

SELL
$1.74 - $2.31 $62,852 - $83,441
-36,122 Reduced 13.81%
225,373 $476,000
Q3 2023

Oct 24, 2023

SELL
$2.11 - $3.28 $99,423 - $154,553
-47,120 Reduced 15.27%
261,495 $554,000
Q2 2023

Jul 13, 2023

BUY
$1.97 - $3.69 $199,955 - $374,535
101,500 Added 49.01%
308,615 $991,000
Q1 2023

May 11, 2023

SELL
$2.14 - $3.4 $73,543 - $116,844
-34,366 Reduced 14.23%
207,115 $449,000
Q4 2022

Feb 08, 2023

SELL
$2.03 - $2.42 $61,630 - $73,471
-30,360 Reduced 11.17%
241,481 $584,000
Q3 2022

Oct 17, 2022

BUY
$1.67 - $2.94 $80,160 - $141,120
48,000 Added 21.44%
271,841 $636,000
Q2 2022

Jul 13, 2022

SELL
$1.19 - $1.65 $41,650 - $57,750
-35,000 Reduced 13.52%
223,841 $346,000
Q1 2022

May 12, 2022

SELL
$0.99 - $1.6 $17,770 - $28,720
-17,950 Reduced 6.49%
258,841 $352,000
Q4 2021

Feb 03, 2022

SELL
$1.22 - $1.72 $9,369 - $13,209
-7,680 Reduced 2.7%
276,791 $337,000
Q3 2021

Nov 02, 2021

SELL
$1.2 - $1.5 $2,580 - $3,225
-2,150 Reduced 0.75%
284,471 $389,000
Q2 2021

Aug 10, 2021

SELL
$1.25 - $1.83 $7,500 - $10,980
-6,000 Reduced 2.05%
286,621 $404,000
Q1 2021

May 07, 2021

SELL
$1.52 - $2.1 $52,721 - $72,838
-34,685 Reduced 10.6%
292,621 $462,000
Q4 2020

Feb 04, 2021

SELL
$1.55 - $2.05 $55,806 - $73,808
-36,004 Reduced 9.91%
327,306 $520,000
Q3 2020

Oct 29, 2020

BUY
$1.59 - $2.19 $4,862 - $6,697
3,058 Added 0.85%
363,310 $632,000
Q2 2020

Jul 27, 2020

BUY
$1.05 - $2.18 $93,408 - $193,932
88,960 Added 32.79%
360,252 $785,000
Q1 2020

May 08, 2020

BUY
$0.89 - $1.49 $19,580 - $32,780
22,000 Added 8.82%
271,292 $322,000
Q4 2019

Feb 04, 2020

BUY
$1.27 - $1.54 $292,413 - $354,580
230,247 Added 1208.96%
249,292 $339,000
Q1 2019

May 08, 2019

SELL
$1.01 - $1.83 $606 - $1,098
-600 Reduced 3.05%
19,045 $0
Q4 2018

Feb 05, 2019

SELL
$0.98 - $1.85 $5,854 - $11,051
-5,974 Reduced 23.32%
19,645 $19,000
Q3 2018

Nov 02, 2018

BUY
$1.76 - $6.38 $26,547 - $96,235
15,084 Added 143.18%
25,619 $0
Q2 2018

Aug 10, 2018

BUY
$3.29 - $4.82 $34,660 - $50,778
10,535 New
10,535 $0

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.51B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.